Reply to the article "Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases" by J.-J.!Body et al. (Ann Oncol 2007; 18: 1165-1171)

被引：0

作者：

Yaman, E. ^{[1
]}

Benekli, M. ^{[1
]}

Coskun, U. ^{[1
]}

Ozturk, B. ^{[1
]}

Kaya, A. O. ^{[1
]}

Yildiz, R. ^{[1
]}

Buyukberber, S. ^{[1
]}

机构：

[1] Gazi Univ, Fac Med, Dept Med Oncol, Ankara, Turkey

来源：

ANNALS OF ONCOLOGY | 2008年 / 19卷 / 02期

关键词：

D O I：

10.1093/annonc/mdm577

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：397 / 398

页数：2

共 8 条

[1] Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases (vol 18, pg 1165, 2007)
Body, J. J.
ANNALS OF ONCOLOGY, 2008, 19 (03) : 601 - 601
[2] Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases
Body, J.-J.
Lichinitser, M.
Tjulandin, S.
Garnero, P.
Bergstroem, B.
ANNALS OF ONCOLOGY, 2007, 18 (07) : 1165 - 1171
[3] Phase III trial of oral ibandronate and intravenous zoledronic acid in breast cancer patients with bone metastases:: comparison of bone turnover markers
Lichinitser, M.
Coleman, R. E.
Tjulandin, S. A.
Bergstrom, B.
Body, J.-J.
EJC SUPPLEMENTS, 2005, 3 (02): : 113 - 113
[4] Non-inferiority of oral ibandronate to intravenous zoledronic acid for reducing markers of bone turnover in metastatic breast cancer patients
Lichinitser, MR
Coleman, RE
Tjulandin, SA
Bergström, B
Body, JJ
BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S259 - S259
[5] Comparative reductions in bone turnover markers with oral ibandronate and intravenous (i.v.) zoledronic acid in patients with bone metastases from breast cancer
Body, J
Lichinitser, M
Tjulandin, S
Garnero, P
Bergström, B
JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 : P67 - P67
[6] Similar reductions in bone turnover markers with oral ibandronate and intravenous (IV) zoledronic acid for bone metastases from breast cancer:: Phase III trial results.
Body, J
Lichinitser, M
Tjulandin, S
Garnero, P
Bergström, B
JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S118 - S118
[7] A comparative phase III trial to determine reductions in bone turnover markers after oral ibandronate or intravenous zoledronic acid treatment in patients with bone metastases from breast cancer
Barrett, M
Lichinitser, M
Body, JJ
Tjulandin, SA
Garnero, P
Bergström, B
ANNALS OF ONCOLOGY, 2005, 16 : 277 - 277
[8] Reply to: Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials (Galvano et al., J Bone Oncol 2019; 18:100252)
Galvano, Antonio
Scaturro, Dalila
Bazan, Viviana
Mauro, Giulia Letizia
Russo, Antonio
JOURNAL OF BONE ONCOLOGY, 2020, 22

← 1 →